Literature DB >> 33741561

Lessons from co-production of evidence and policy in Nigeria's COVID-19 response.

Ibrahim Abubakar1, Sarah L Dalglish2, Chikwe A Ihekweazu3, Omotayo Bolu4, Sani H Aliyu5.   

Abstract

In February 2020, Nigeria faced a potentially catastrophic COVID-19 outbreak due to multiple introductions, high population density in urban slums, prevalence of other infectious diseases and poor health infrastructure. As in other countries, Nigerian policymakers had to make rapid and consequential decisions with limited understanding of transmission dynamics and the efficacy of available control measures. We present an account of the Nigerian COVID-19 response based on co-production of evidence between political decision-makers, health policymakers and academics from Nigerian and foreign institutions, an approach that allowed a multidisciplinary group to collaborate on issues arising in real time. Key aspects of the process were the central role of policymakers in determining priority areas and the coordination of multiple, sometime conflicting inputs from stakeholders to write briefing papers and inform effective national decision making. However, the co-production approach met with some challenges, including limited transparency, bureaucratic obstacles and an overly epidemiological focus on numbers of cases and deaths, arguably to the detriment of addressing social and economic effects of response measures. Larger systemic obstacles included a complex multitiered health system, fragmented decision-making structures and limited funding for implementation. Going forward, Nigeria should strengthen the integration of the national response within existing health decision bodies and implement strategies to mitigate the social and economic impact, particularly on the poorest Nigerians. The co-production of evidence examining the broader public health impact, with synthesis by multidisciplinary teams, is essential to meeting the social and public health challenges posed by the COVID-19 pandemic in Nigeria and other countries. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Entities:  

Keywords:  COVID-19; control strategies; health policy; health services research; mathematical modelling

Mesh:

Year:  2021        PMID: 33741561      PMCID: PMC7985933          DOI: 10.1136/bmjgh-2020-004793

Source DB:  PubMed          Journal:  BMJ Glob Health        ISSN: 2059-7908


  17 in total

1.  Africa's pandemic puzzle: why so few cases and deaths?

Authors:  Linda Nordling
Journal:  Science       Date:  2020-08-14       Impact factor: 47.728

2.  Modeling infectious disease dynamics.

Authors:  Sarah Cobey
Journal:  Science       Date:  2020-04-24       Impact factor: 47.728

3.  The major genetic risk factor for severe COVID-19 is inherited from Neanderthals.

Authors:  Hugo Zeberg; Svante Pääbo
Journal:  Nature       Date:  2020-09-30       Impact factor: 49.962

4.  Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study.

Authors:  Timothy Roberton; Emily D Carter; Victoria B Chou; Angela R Stegmuller; Bianca D Jackson; Yvonne Tam; Talata Sawadogo-Lewis; Neff Walker
Journal:  Lancet Glob Health       Date:  2020-05-12       Impact factor: 26.763

5.  Coronavirus outbreak in Nigeria: Burden and socio-medical response during the first 100 days.

Authors:  Jimoh Amzat; Kafayat Aminu; Victor I Kolo; Ayodele A Akinyele; Janet A Ogundairo; Maryann C Danjibo
Journal:  Int J Infect Dis       Date:  2020-06-22       Impact factor: 3.623

6.  COVID-19 in Nigeria: a disease of hunger.

Authors:  Bernard Kalu
Journal:  Lancet Respir Med       Date:  2020-04-29       Impact factor: 30.700

7.  Demographic perspectives on the mortality of COVID-19 and other epidemics.

Authors:  Joshua R Goldstein; Ronald D Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-20       Impact factor: 11.205

8.  COVID-19 gives the lie to global health expertise.

Authors:  Sarah L Dalglish
Journal:  Lancet       Date:  2020-03-26       Impact factor: 79.321

9.  High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa.

Authors:  For Yue Tso; Salum J Lidenge; Phoebe B Peña; Ashley A Clegg; John R Ngowi; Julius Mwaiselage; Owen Ngalamika; Peter Julius; John T West; Charles Wood
Journal:  Int J Infect Dis       Date:  2020-11-08       Impact factor: 3.623

10.  Descriptive epidemiology of coronavirus disease 2019 in Nigeria, 27 February-6 June 2020.

Authors:  K O Elimian; C L Ochu; E Ilori; J Oladejo; E Igumbor; L Steinhardt; J Wagai; C Arinze; W Ukponu; C Obiekea; O Aderinola; E Crawford; A Olayinka; C Dan-Nwafor; T Okwor; Y Disu; A Yinka-Ogunleye; N E Kanu; O A Olawepo; O Aruna; C A Michael; L Dunkwu; O Ipadeola; D Naidoo; C D Umeokonkwo; A Matthias; O Okunromade; S Badaru; A Jinadu; O Ogunbode; A Egwuenu; A Jafiya; M Dalhat; F Saleh; G B Ebhodaghe; A Ahumibe; R U Yashe; R Atteh; W E Nwachukwu; C Ezeokafor; D Olaleye; Z Habib; I Abdus-Salam; E Pembi; D John; U J Okhuarobo; H Assad; Y Gandi; B Muhammad; C Nwagwogu; I Nwadiuto; K Sulaiman; I Iwuji; A Okeji; S Thliza; S Fagbemi; R Usman; A A Mohammed; O Adeola-Musa; M Ishaka; U Aketemo; K Kamaldeen; C E Obagha; A O Akinyode; P Nguku; N Mba; C Ihekweazu
Journal:  Epidemiol Infect       Date:  2020-09-11       Impact factor: 2.451

View more
  6 in total

Review 1.  The Lancet Nigeria Commission: investing in health and the future of the nation.

Authors:  Ibrahim Abubakar; Sarah L Dalglish; Blake Angell; Olutobi Sanuade; Seye Abimbola; Aishatu Lawal Adamu; Ifedayo M O Adetifa; Tim Colbourn; Afolabi Olaniyi Ogunlesi; Obinna Onwujekwe; Eme T Owoaje; Iruka N Okeke; Adebowale Adeyemo; Gambo Aliyu; Muktar H Aliyu; Sani Hussaini Aliyu; Emmanuel A Ameh; Belinda Archibong; Alex Ezeh; Muktar A Gadanya; Chikwe Ihekweazu; Vivianne Ihekweazu; Zubairu Iliyasu; Aminatu Kwaku Chiroma; Diana A Mabayoje; Mohammed Nasir Sambo; Stephen Obaro; Adesola Yinka-Ogunleye; Friday Okonofua; Tolu Oni; Olu Onyimadu; Muhammad Ali Pate; Babatunde L Salako; Faisal Shuaib; Fatimah Tsiga-Ahmed; Fatima H Zanna
Journal:  Lancet       Date:  2022-03-15       Impact factor: 202.731

2.  Implementing an emergency risk communication campaign in response to the COVID-19 pandemic in Nigeria: lessons learned.

Authors:  Vivianne Ihekweazu; Ukwori Ejibe; Chijioke Kaduru; Yahya Disu; Oyeronke Oyebanji; Emeka Oguanuo; Chimezie Anueyiagu; Oreoluwa Oluwabukunola Obanor; Atinuke Akande-Alegbe; Abiodun Egwuenu; Tijesu Ojumu; Abara Erim Abara; Chinwe Lucia Ochu
Journal:  BMJ Glob Health       Date:  2022-06

3.  Epidemiological comparison of the first and second waves of the COVID-19 pandemic in Nigeria, February 2020-April 2021.

Authors:  Oluwatosin Wuraola Akande; Kelly Osezele Elimian; Ehimario Igumbor; Lauryn Dunkwu; Chijioke Kaduru; Olubunmi Omowunmi Olopha; Dabri Olohije Ohanu; Lilian Nwozor; Emmanuel Agogo; Olusola Aruna; Muhammad Shakir Balogun; Olaolu Aderinola; Anthony Ahumibe; Chinedu Arinze; Sikiru Olanrewaju Badaru; William Nwachukwu; Augustine Olajide Dada; Cyril Erameh; Khadeejah Hamza; Tarik Benjamin Mohammed; Nnaemeka Ndodo; Celestina Obiekea; Chinenye Ofoegbunam; Oladipo Ogunbode; Cornelius Ohonsi; Ekaete Alice Tobin; Rimamdeyati Yashe; Afolabi Adekaiyaoja; Michael C Asuzu; Rosemary Ajuma Audu; Muhammad Bashir Bello; Shaibu Oricha Bello; Yusuf Yahaya Deeni; Yahya Disu; Gbenga Joseph; Chidiebere Ezeokafor; Zaiyad Garba Habib; Christian Ibeh; Ifeanyi Franklin Ike; Emem Iwara; Rejoice Kudirat Luka-Lawal; Geoffrey Namara; Tochi Okwor; Lois Olajide; Oluwafunke Olufemi Ilesanmi; Solomon Omonigho; Ferdinand Oyiri; Koubagnine Takpa; Nkem Usha Ugbogulu; Priscilla Ibekwe; John Oladejo; Elsie Ilori; Chinwe Lucia Ochu; Chikwe Ihekweazu
Journal:  BMJ Glob Health       Date:  2021-11

Review 4.  A critical evaluation of Nigeria's response to the first wave of COVID-19.

Authors:  Ezekiel Damilare Jacobs; Malachy Ifeanyi Okeke
Journal:  Bull Natl Res Cent       Date:  2022-02-24

5.  SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa.

Authors:  Adam Abdullahi; David Oladele; Michael Owusu; Steven A Kemp; James Ayorinde; Abideen Salako; Douglas Fink; Fehintola Ige; Isabella A T M Ferreira; Bo Meng; Augustina Angelina Sylverken; Chika Onwuamah; Kwame Ofori Boadu; Kazeem Osuolale; James Opoku Frimpong; Rufai Abubakar; Azuka Okuruawe; Haruna Wisso Abdullahi; Gideon Liboro; Lawrence Duah Agyemang; Nana Kwame Ayisi-Boateng; Oluwatosin Odubela; Gregory Ohihoin; Oliver Ezechi; Japhet Senyo Kamasah; Emmanuel Ameyaw; Joshua Arthur; Derrick Boakye Kyei; Dorcas Ohui Owusu; Olagoke Usman; Sunday Mogaji; Adedamola Dada; George Agyei; Soraya Ebrahimi; Lourdes Ceron Gutierrez; Sani H Aliyu; Rainer Doffinger; Rosemary Audu; Richard Adegbola; Petra Mlcochova; Richard Odame Phillips; Babatunde Lawal Solako; Ravindra K Gupta
Journal:  Nat Commun       Date:  2022-10-17       Impact factor: 17.694

6.  Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria.

Authors:  OgoChukwu Vincent Okpala; Cyril Chukwudi Dim; Chukwuebuka Immanuel Ugwu; Simeon Onyemaechi; Obiageli Uchebo; Ugochukwu Chukwulobelu; Chuma Emembolu; Ben Okoye; Chukwumuanya Igboekwu; Uchenna Benedict Okoye; Nelly Chibuzor Dike; Anastasia Obiageli Odumegwu; Christopher Ideh; Ngozi Christiana Okoye; Vincent Chinedu Okpala; Peter Ikenna Okoye; Maryann Chinyere Enike; Oluchi Onyedikachi
Journal:  Int J Infect Dis       Date:  2021-07-19       Impact factor: 3.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.